INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 430m ago
HOUSE PTR29m ago
SEC 13F29m ago
ROBINHOOD CHAIN29m ago
SEC FORM 4/Grant or awardVerified data

Tenjarla Srini reported SER

SVP, CMC & Formulation · Serina Therapeutics, Inc. · Serina Therapeutics, Inc. — Stock Option (right to buy)

Side
A
Value
—
Shares
85.6K
Price
—
Executed
May 21, 2026
Disclosed
May 26, 2026
Disclosure timeline5 days from execution to publication · legal deadline 2 business days
May 21 executedMay 26, 2026 disclosed

SER · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
15/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing+6 / 15

    Disclosed 3 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · SER

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    11
    MP
    Marshall Richard PeterDirector
    SERSerina Therapeutics, Inc.
    Grant or award
    		A—
    15.3K sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    47
    MP
    Marshall Richard PeterDirector
    SERSerina Therapeutics, Inc.
    Open-market purchase
    		BUY$20K
    12.2K sh
    		May 19, 2026May 22, 2026
    traded May 19, 2026
    		+3dSEC FORM 4

    Evidence

    19
    TS
    Tenjarla SriniSVP, CMC & Formulation
    SERSerina Therapeutics, Inc.
    Grant or award
    		A—
    69.0K sh
    		Feb 3, 2026Feb 17, 2026
    traded Feb 3, 2026
    		+14dSEC FORM 4

    Evidence

    9
    BK
    Brannan Stephen K.Director
    SERSerina Therapeutics, Inc.
    Grant or award
    		A—
    10.0K sh
    		Nov 7, 2025Nov 10, 2025
    traded Nov 7, 2025
    		+3dSEC FORM 4

    Evidence

    9
    MP
    Marshall Richard PeterDirector
    SERSerina Therapeutics, Inc.
    Grant or award
    		A—
    10.0K sh
    		Nov 7, 2025Nov 10, 2025
    traded Nov 7, 2025
    		+3dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002029985-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    May 21, 2026
    Published
    May 26, 2026
    Ingested by INSIDER
    Nov 5, 03:56 UTC
    Last re-read
    Nov 5, 03:56 UTC

    Extracted facts

    Filer
    Tenjarla Srini
    Role
    SVP, CMC & Formulation
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Serina Therapeutics, Inc. — Stock Option (right to buy)
    Ticker
    SER
    Shares
    85.6K
    Price per share
    $0
    Execution date (reported)
    May 21, 2026
    Owned after transaction
    85.6K shares
    Days from execution to publication
    5

    What this establishes

    Tenjarla Srini filed this Form 4 reporting a grant or award of SER on May 21, 2026. It became public on May 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, CMC & Formulation
    Tenjarla Srinicik:0002029985
    Issuer
    Serina Therapeutics, Inc.cik:0001708599

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.